Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor

Human tumors exhibit increased glucose uptake and metabolism as a result of high demand for ATP and anabolic substrates and this metabolotype is a negative prognostic indicator for survival. Recent studies have demonstrated that cancer cells from several tissue origins and genetic backgrounds require the expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4), a regulatory enzyme that synthesizes an allosteric activator of glycolysis, fructose-2,6-bisphosphate. We report the discovery of a first-in-class PFKFB4 inhibitor, 5-(n-(8-methoxy-4-quinolyl)amino)pentyl nitrate (5MPN), using structure-based virtual computational screening. We find that 5MPN is a selective inhibitor of PFKFB4 that suppresses the glycolysis and proliferation of multiple human cancer cell lines but not non-transformed epithelial cells in vitro. Importantly, 5MPN has high oral bioavailability and per os administration of a non-toxic dose of 5MPN suppresses the glucose metabolism and growth of tumors in mice.

[1]  A. Lane,et al.  Fructose-2,6-Bisphosphate synthesis by 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth , 2014, Oncotarget.

[2]  A. Yalçin,et al.  6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27 , 2014, Cell Death and Disease.

[3]  J. Trent,et al.  Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer , 2013, Molecular Cancer Therapeutics.

[4]  G. Reifenberger,et al.  RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival , 2012, Oncogene.

[5]  Gavin Kelly,et al.  Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. , 2012, Cancer discovery.

[6]  A. Yalçin,et al.  Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. , 2009, Experimental and molecular pathology.

[7]  A. Lane,et al.  Nuclear Targeting of 6-Phosphofructo-2-kinase (PFKFB3) Increases Proliferation via Cyclin-dependent Kinases* , 2009, The Journal of Biological Chemistry.

[8]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[9]  A. Lane,et al.  Ras transformation requires metabolic control by 6-phosphofructo-2-kinase , 2006, Oncogene.

[10]  Tina Mlakar,et al.  Citrate Inhibition-Resistant Form of 6-Phosphofructo-1-Kinase from Aspergillus niger , 2006, Applied and Environmental Microbiology.

[11]  H. Esumi,et al.  Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. , 2005, Biochimie.

[12]  J. Caro,et al.  Hypoxic regulation of the 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase gene family (PFKFB‐1–4) expression in vivo , 2003, FEBS letters.

[13]  B. Rollins,et al.  DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras , 2003, Oncogene.

[14]  Rodrigo Lopez,et al.  Multiple sequence alignment with the Clustal series of programs , 2003, Nucleic Acids Res..

[15]  Ajay N. Jain.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[16]  R. G. Kemp,et al.  Evolution of the allosteric ligand sites of mammalian phosphofructo-1-kinase. , 2002, Biochemistry.

[17]  R. Sakakibara,et al.  Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase. , 1997, Journal of biochemistry.

[18]  J. Deisenhofer,et al.  The crystal structure of the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase reveals distinct domain homologies. , 1996, Structure.

[19]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[20]  K. Uyeda,et al.  Molecular cloning of the DNA and expression and characterization of rat testes fructose-6-phosphate,2-kinase:fructose-2,6-bisphosphatase. , 1991, The Journal of biological chemistry.

[21]  T. Murakami,et al.  The cell cycle associated change of the Ki‐67 reactive nuclear antigen expression , 1987, Journal of cellular physiology.

[22]  M. Lively,et al.  Isolation of a cDNA clone for rat liver 6-phosphofructo 2-kinase/fructose 2,6-bisphosphatase. , 1987, Biochemical and biophysical research communications.

[23]  J. Venditti,et al.  Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. , 1987, Cancer treatment reports.

[24]  J. Correia,et al.  Tissue distribution, immunoreactivity, and physical properties of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  E. Schaftingen,et al.  A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate. , 1982, European journal of biochemistry.

[26]  E. Schaftingen,et al.  Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase. , 1980, The Biochemical journal.

[27]  E. Schaftingen,et al.  Synthesis of a stimulator of phosphofructokinase, most likely fructose 2,6-bisphosphate, from phosphoric acid and fructose 6-phosphoric acid. , 1980, Biochemical and biophysical research communications.

[28]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[29]  H. Esumi,et al.  Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines. , 2005, Acta biochimica Polonica.

[30]  H. Esumi,et al.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor. , 2005, Ukrains'kyi biokhimichnyi zhurnal.

[31]  R. G. Kemp,et al.  Allosteric regulatory properties of muscle phosphofructokinase , 2004, Molecular and Cellular Biochemistry.